Clinical Trials at Stanford Cancer Center
As of September 2026, 20 paid clinical trials are recruiting at Stanford Cancer Center, located at 3373 HILLVIEW AVE, PALO ALTO, CA 94304, phone (650) 723-5548 in Palo Alto, California. Active studies at this site cover conditions such as Breast Cancer, Chronic Lymphocytic Leukemia and Epilepsy. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
20 clinical trials at Stanford Cancer Center
·Clear filters·Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
Common conditions studied in Palo Alto
- Cancer (8 active studies)
- Breast Cancer (7 active studies)
- Chronic Lymphocytic Leukemia (7 active studies)
- Epilepsy (7 active studies)
- Heart Failure (7 active studies)
- Acute Myeloid Leukemia (6 active studies)
Leading research sponsors in Palo Alto
- Stanford University
- VA Office of Research and Development
- National Cancer Institute (NCI)
- Children's Oncology Group
- NRG Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Palo Alto?
There are approximately 654 recruiting clinical trials in Palo Alto, California listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Palo Alto pay participants?
Most recruiting trials in Palo Alto compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Palo Alto?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Palo Alto?
The most common conditions under active study in Palo Alto include Cancer (8), Breast Cancer (7), Chronic Lymphocytic Leukemia (7), Epilepsy (7), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Palo Alto?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Palo Alto on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Palo Alto?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Palo Alto?
Recruiting research sites in Palo Alto include Stanford University, Stanford Cancer Institute Palo Alto, Stanford University Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Palo Alto right now?
The largest active categories in Palo Alto are Cancer & tumors (187), Neurology & pain (44), Cardiovascular (36). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Stanford Cancer Center?
Stanford Cancer Center is located at 3373 HILLVIEW AVE, PALO ALTO, CA 94304. Use the Google Maps link in the intro above to get directions.
How do I contact Stanford Cancer Center?
You can reach Stanford Cancer Center by phone at (650) 723-5548. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.